Zacks: Analysts Anticipate Vericel Corp (VCEL) to Post -$0.10 EPS

Equities analysts predict that Vericel Corp (NASDAQ:VCEL) will post earnings of ($0.10) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vericel’s earnings. Vericel posted earnings per share of ($0.14) in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The company is expected to report its next quarterly earnings report on Friday, March 9th.

On average, analysts expect that Vericel will report full-year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.56). For the next year, analysts anticipate that the firm will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.48) to ($0.24). Zacks’ EPS calculations are an average based on a survey of research firms that follow Vericel.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.01. The company had revenue of $14.26 million during the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%.

A number of brokerages recently issued reports on VCEL. ValuEngine upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BTIG Research set a $8.00 price objective on Vericel and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $9.00 price objective on shares of Vericel in a research note on Tuesday, January 2nd.

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in Vericel by 1,374.2% in the 4th quarter. Wells Fargo & Company MN now owns 30,029 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 27,992 shares during the period. First Washington CORP boosted its stake in Vericel by 20.1% in the 4th quarter. First Washington CORP now owns 809,027 shares of the biotechnology company’s stock worth $4,409,000 after purchasing an additional 135,600 shares during the period. Perkins Capital Management Inc. boosted its stake in Vericel by 2.9% in the 4th quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock worth $3,155,000 after purchasing an additional 16,350 shares during the period. Bank of Montreal Can bought a new position in Vericel in the 4th quarter worth approximately $140,000. Finally, Citadel Advisors LLC bought a new position in Vericel in the 3rd quarter worth approximately $235,000. Institutional investors and hedge funds own 33.06% of the company’s stock.

Vericel (NASDAQ VCEL) opened at $7.15 on Friday. The stock has a market capitalization of $251.34, a P/E ratio of -8.13 and a beta of 3.34. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50. Vericel has a 52 week low of $2.35 and a 52 week high of $8.25.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate Vericel Corp (VCEL) to Post -$0.10 EPS” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/09/zacks-analysts-anticipate-vericel-corp-vcel-to-post-0-10-eps.html.

About Vericel

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply